Table 1 Characterisation of patients included in the present analyses by immunoparesis of polyclonal IgM (within normal range versus below normal range) from those enroled in MRC myeloma trials from 1980 to 1997 (old trials) compared to the MRC Myeloma IX trial (2003–2008) and the ongoing NCRI Myeloma XI trial (2010–2016)
Old trials (MIV, MV, MVI and MVIII) | Recent trials (MIX and MXI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Factor | Grouping | IgM within NR N = 535 | IgM below NR N = 2073 | Total N = 2608 | p | IgM within NR N = 348 | IgM below NR N = 2870 | Total N = 3218 | p |
Gender | Male | 298 (56%) | 1196 (58%) | 1494 (57%) | .45 | 198 (58%) | 1645 (59%) | 1843 (59%) | .77 |
Female | 236 (44%) | 876 (42%) | 1112 (43%) | 144 (42%) | 1148 (41%) | 1292 (41%) | |||
Age group | <65 years | 287 (54%) | 1018 (49%) | 1305 (50%) | .07 | 169 (49%) | 1226 (43%) | 1395 (44%) | .05 |
≥65 years | 248 (46%) | 1051 (51%) | 1299 (50%) | 179 (51%) | 1632 (57%) | 1811 (56%) | |||
Pathway | Intensive | – | – | – | – | 210 (60%) | 1627 (57%) | 1837 (57%) | .21 |
Non-intensive | – | – | – | – | 138 (40%) | 1243 (43%) | 1381 (43%) | ||
M-protein type | IgG | 343 (64%) | 1131 (55%) | 1474 (56%) | .001 | 231 (66%) | 1700 (59%) | 1931 (60%) | .002 |
IgA | 123 (23%) | 580 (28%) | 703 (27%) | 60 (17%) | 708 (25%) | 768 (24%) | |||
IgD | 4 (1%) | 36 (2%) | 40 (2%) | 4 (1%) | 51 (2%) | 55 (2%) | |||
IgE | 1 (<1) | 1 (<1) | 2 (<1%) | – | – | – | |||
Light chain only | 55 (10%) | 296 (14%) | 351 (13%) | 43 (12%) | 370 (13%) | 413 (13%) | |||
Non-secretory | 9 (2%) | 29 (1%) | 38 (1%) | 7 (2%) | 17 (1%) | 24 (1%) | |||
Oligosecretory | – | – | – | 3 (1%) | 24 (1%) | 27 (1%) | |||
% BMPCs | <20 | 152 (40%) | 331 (21%) | 483 (24%) | <.0001 | 189 (61%) | 774 (29%) | 963 (32%) | <.0001 |
20–50 | 156 (41%) | 724 (45%) | 880 (44%) | 99 (32%) | 1182 (45%) | 1281 (43%) | |||
>50 | 76 (20%) | 559 (35%) | 635 (32%) | 23 (7%) | 699 (26%) | 722 (24%) | |||
Sb2m (mg/l) | ≤4 | 208 (40%) | 460 (23%) | 668 (26%) | <.0001 | 235 (68%) | 1317 (46%) | 1552 (48%) | <.0001 |
4–8 | 195 (37%) | 807 (40%) | 1002 (39%) | 89 (26%) | 1069 (37%) | 1158 (36%) | |||
>8 | 117 (23%) | 765 (38%) | 822 (35%) | 23 (6%) | 480 (17%) | 503 (16%) | |||
Albumin (g/l) | <30 | 79 (22%) | 458 (29%) | 537 (27%) | .001 | 55 (17%) | 559 (20%) | 614 (20%) | .008 |
30–35 | 106 (30%) | 535 (33%) | 641 (33%) | 81 (24%) | 846 (30%) | 927 (30%) | |||
>35 | 174 (48%) | 612 (38%) | 786 (40%) | 195 (59%) | 1397 (50%) | 1592 (51%) | |||
eGFR ml/min | <30 | 89 (17%) | 453 (22%) | 542 (21%) | .0003 | 19 (6%) | 287 (10%) | 306 (10%) | .008 |
30–60 | 230 (43%) | 961 (46%) | 1191 (46%) | 116 (34%) | 995 (36%) | 1111 (35%) | |||
>60 | 215 (40%) | 654 (32%) | 869 (33%) | 207 (60%) | 1502 (54%) | 1709 (55%) | |||
ISS | I | 81 (17%) | 146 (7%) | 227 (9%) | <.0001 | 134 (41%) | 608 (22%) | 742 (24%) | <.0001 |
II | 169 (36%) | 617 (32%) | 786 (33%) | 128 (39%) | 1086 (40%) | 1214 (40%) | |||
III | 214 (46%) | 1189 (61%) | 1403 (58%) | 67 (20%) | 1024 (38%) | 1091 (36%) | |||
LDH IU/L | <273 | – | – | – | 92 (36%) | 892 (42%) | 984 (41%) | .07 | |
≥273 | – | – | – | 163 (64%) | 1224 (58%) | 1387 (59%) | |||
Genetic risk | Standard risk | – | – | – | 115 (33%) | 798 (28%) | 913 (28%) | <.0001a | |
High risk | – | – | – | 43 (12%) | 694 (24%) | 737 (23%) | |||
Unknown | 190 (55%) | 1378 (48%) | 1568 (49%) | ||||||
